Join us for yet another episode of The Oncology Brothers podcast, where we delve into the FRESCO2 study in metastatic colorectal cancer. In this episode, we are joined by Dr. Arvind Dasari from MD Anderson, the lead author of the study, to discuss the approval of fruquintinib and its impact on refractory colorectal cancer patients. Discover how fruquintinib has significantly improved progression-free and overall survival, providing a new treatment option for patients who have exhausted other therapies. Dr. Dasari shares insights on the study design, results, and the practical implications of incorporating fruquintinib into clinical practice. Tune in to learn about the key findings, side effects, dosing strategies, and real-world experiences with fruquintinib in managing refractory colorectal cancer. Take advantage of this informative episode that sheds light on the evolving landscape of colon cancer treatments. Subscribe to The Oncology Brothers podcast for more insightful discussions on cancer care. #Oncology #ColorectalCancer #FRESCO2Study

Welcome to another insightful episode of the Oncology Brothers podcast! In this episode, hosts Rahul and Rohit Gosain are joined by Dr. Sam Klempner, a medical oncologist specializing in upper GI malignancies. Together, they delve into the current treatment strategies for esophageal, GE junction, and gastric adenocarcinoma.   The discussion covers a range of topics, including the evolving paradigms in neoadjuvant and adjuvant therapies, the importance of biomarker testing such as MSI and PD-L1, and the potential impact of new targets like Claudin 18.2 in upper GI cancers. Dr. Klempner also shares insights on the management of metastatic disease, including the role of targeted therapies like TDXD and Zolbetuximab.   Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode provides valuable information on the current landscape of upper GI malignancies. Stay informed and join the Oncology Brothers as they navigate the complexities of treating these challenging cancers. Don't miss out on this informative discussion!   Tune in to the Oncology Brothers podcast for more expert insights and discussions on oncology topics. Remember to like, share, and subscribe for more content on the latest developments in cancer care. Thank you for listening!   Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

In this episode of Oncology Brothers, join hosts Drs. Rahul and Rohit as they dive into the management of colon cancer with special guest Dr. Aparna Parikh, a medical oncologist from Mass General Hospital. Dr. Parikh shares insights on the treatment algorithm for colon cancer, including the use of circulating tumor DNA and the latest advancements in treatment options. From localized disease to metastatic space, the discussion covers key aspects of managing colon cancer. Tune in to learn about the evolving landscape of colon cancer treatment and the importance of personalized patient-centered care. Don't miss out on this informative episode with the Oncology Brothers and Dr. Aparna Parikh!

Join the Oncology Brothers, Drs. Rahul and Rohit Gosain, in this engaging podcast episode as they delve into the treatment landscape for hepatocellular carcinoma (HCC) with Dr. Tanios S. Bekaii-saab from Mayo Clinic. The discussion covers the treatment options for different stages of HCC, including liver transplant, local therapy, and systemic treatments. Dr. Tanios S. Bekaii-saab provides insights on utilizing Atezolizumab with Bevacizumab, dual checkpoint inhibitors, and TKIs in advanced or metastatic HCC. Clinical pearls on managing side effects and patient selection criteria are also discussed. Don't miss this comprehensive overview of HCC treatment strategies in both community and academic settings. Stay informed and educated on the latest developments in oncology with the Oncology Brothers podcast series. Subscribe now for more insightful discussions on various cancer types and treatment approaches. #Oncology #HepatocellularCarcinoma #CancerTreatment #PodcastEpisode

Join the Oncology Brothers, Drs. Rahul and Rohit Gosain, as they dive deep into the groundbreaking EV302 study with special guest Dr. Thomas Powles. In this episode, they discuss the approval of Enfortumab and Pembrolizumab as a combination therapy for advanced bladder cancer, based on the remarkable results of the study. Dr. Powles shares insights on the study design, findings, and the transformative impact of the treatment on patients' lives. Discover how this new standard of care in bladder cancer has significantly improved overall survival benefits, with a median survival of 31.5 months compared to 16.1 months with chemotherapy. The discussion also delves into managing the side effects of the treatment and the potential use of ctDNA in monitoring disease progression. Don't miss this informative episode that sheds light on the evolving landscape of bladder cancer treatment and the hope it brings to patients. Stay tuned for a quick recap and insights from the Oncology Brothers.

Bladder Cancer Treatment Options: A Comprehensive Discussion | Oncology Brothers Podcast   Join the Oncology Brothers, Rahul Gosain and Rohit Gosain, in this insightful podcast episode where they are joined by Dr. Karine Tawagi, a medical oncologist, and Dr. Sia Daneshmand, a urologist, to discuss the current standard of care and treatment options for bladder cancer. In this episode, the experts delve into the treatment approaches for non-muscle invasive bladder cancer, including the use of BCG, pembrolizumab, and other emerging therapies. They also cover the management of muscle invasive bladder cancer, highlighting the role of neoadjuvant chemotherapy, cystectomy, and immunotherapy. The conversation extends to metastatic bladder cancer, focusing on the groundbreaking EV Pembro treatment and the evolving landscape of treatment options post-progression. The experts provide valuable insights into managing toxicities associated with different therapies and offer clinical pearls for healthcare providers. Don't miss this informative discussion on bladder cancer treatment options, featuring expert insights and practical recommendations for healthcare professionals. Tune in to the Oncology Brothers Podcast now! Listen to the full episode here. Stay informed and updated on the latest advancements in oncology with the Oncology Brothers podcast series. Subscribe now for more engaging discussions and expert insights. #Bladder #Cancer #Treatment #Algorithm Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

In this episode joined by Dr. Monty Pal from City of Hope to discuss the latest advancements in the treatment of renal cell cancer. The conversation covers topics such as adjuvant pembrolizumab, personalized medicine, second-line treatment options, and the role of TKIs and immune checkpoint inhibitors. Dr. Pal shares insights on clinical pearls, treatment algorithms, and ongoing clinical trials in the field. Tune in to stay informed about the current standard of care practices in renal cell cancer treatment. Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

In discussion with Dr. Rana McKay, Associate Professor of Medicine from UC San Diego Health, we covered the treatment algorithm for Prostate cancer, starting from localized disease and then focusing on CSPC and CRPC. #Prostate #Cancer #Cancer #2024 #oncology #oncbrothers Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

In this discussion with Dr. Hope Rugo, we covered her study Capitello-291, which led to the approval of Capivasertib in hormone receptor-positive breast cancer with AKT1, PTEN, and PIK3CA mutations, which are seen in 40-50% of the cases. We touched base on sequencing of this therapy, and important clinical pearls around the side effect management associated with this drug.

In discussion with Dr. Virginia Kaklamani, we cover treatment algorithm of HR+ breast cancer. We covered the current standard of care treatment options for HR+ breast cancer.   #HER2 #Sensitive #Breast #Cancer #2024 #oncology #oncbrothers   Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

In discussion with Dr. Tian Zhang, covering the Genitourinary ASCO 2024 meeting highlights from the Community Oncology perspective. We covered 4 important practice informing studies from GU ASCO with Dr. Zhang: - CONTACT-02: Phase 3 study of cabozantinib plus atezolizumab vs second novel hormonal therapy in patients with metastatic castration-resistant prostate cancer - BRCAAway: A randomized phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in patients with metastatic castration-resistant prostate cancer bearing homologous recombination-repair mutations - AMBASSADOR: Phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma vs observation - Keynote-564: Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma

In discussion with Dr. Harold Burstein, we cover treatment algorithm of HER2+ breast cancer. We covered the current standard of care treatment options for HER2+ breast cancer. #HER2 #Sensitive #Breast #Cancer #2024 #oncology #oncbrothers Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

In discussion with Dr. Pamela Kunz, covering the Gastroenterology ASCO 2024 meeting highlights from Community Oncology perspective. We covered 3 important practice informing studies from GI ASCO with Dr. Kunz: - CheckMate 8HW: Nivolumab plus ipilimumab vs chemotherapy as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer - EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization - NETTER-2: [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors

Discussing the management using the algorithm of Triple Negative Breast Cancer (TNBC) - with Dr. Ruth O'Regan Chair of medicine Charles A. Dewey Professor at the University of Rochester Wilmot Cancer Institute & Dr. Anna Weiss Associate Professor - Department of Surgery, Oncology Wilmot Cancer Institute.

In discussion with Dr. Uma Borate from the Ohio State University Comprehensive Cancer Center, The James, covering the leukemia, myelofibrosis and myelodysplastic syndrome key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Borate: - TRANSFORM-1: Ph III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, International, Study of Navitoclax in Combination with Ruxolitinib vs Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis - MANIFEST-2: Ph III, Randomized, Double-Blind Study, Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis - SAVE: Phase I/II, Investigating the All-Oral Combination of the Menin Inhibitor Revumenib (SNDX-5613) with Decitabine/Cedazuridine (ASTX727) and Venetoclax in AML - AUGMENT-101: Ph I/II, Revumenib Monotherapy in Patients with R/R KMT2Ar Acute Leukemias: Efficacy and Safety Results #ASH #Leukemia #MDS #Myelofibrosis #Blood #Cancer #2023 #oncology #oncbrothers Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

In discussion with Dr. Daniel G. Stover, covering the San Antonio Breast Cancer Symposium 2023 Highlights from Community Oncology perspective. We covered 3 important practice informing studies in HER2+ disease with Dr. Stover: - APHINITY Sub-analysis: Benefit of Adj Pertuzumab and Trastuzumab According to ER and HER2 Expression - KATHERINE Update: Phase III Study of Adjuvant TDM-1 vs Trastuzumab for Residual Invasive HER2-positive Early Breast Cancer After Neoadj Chemo: Final IDFS and Updated OS analysis - HER2CLIMB-02: Randomized, Double-blind Phase 3 Trial of Tucatinib and TDM1 for Previously Treated HER2-positive Metastatic Breast Cancer

In discussion with Dr. Hope Rugo, covering the San Antonio Breast Cancer Symposium 2023 Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Rugo: - NATALEE Update – Ribociclib + Nonsteroidal AI as Adj Treatment in Patients with HR+/HER2− Early Breast Cancer: Final iDFS analysis - MONARCH 3 – Final OS Results of Abemaciclib Plus a Nonsteroidal AI as First-line Therapy for HR+, HER2– Advanced Breast Cancer - INAVO120 – Phase III Study of Inavolisib or Placebo in Combination with Palbociclib and Fulvestrant in Patients with PIK3CA-mut, HR+, HER2– Locally Adv/Metastatic Breast Cancer - TROPION-Breast01 – Phase III Study of Dato-DXd vs Chemo for Patients with Previously Treated Inoperable/Metastatic HR+, HER2– Breast Cancer

In discussion with Dr. Mazyar Shadman from the Fred Hutch Cancer Center, covering the Chronic Lymphocytic Leukemia and Lymphoma key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Shadman: - ALPINE: Ph 3, Extended Follow-up Confirms Sustained Superior PFS of Zanubrutinib vs Ibrutinib for Treatment of R/R Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma - SEQUOIA: Ph 3, Broad Superiority of Zanubrutinib Over BR Across Multiple High-Risk Factors: Biomarker Subgroup Analysis in the Treatment-Naive Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) without del(17p) - SWOG S1826: Nivolumab-AVD Is Better Tolerated and Improves PFS Compared to Bv-AVD in Older Patients (Aged ≥60 Years) with Advanced Stage Hodgkin Lymphoma - POLARIX Update: Deciphering the Clinical Benefit of Pola-R-CHP versus R-CHOP in Different Genetic Subtypes Beyond Cell of Origin in the POLARIX Study

In discussion with Dr. Jens Hillengasss from Roswell Park Comprehensive Cancer Center, covering the Multiple Myeloma key practice changing/informing abstracts from American Society of Hematology (ASH) 2023 conference from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Hillengass: - PERSEUS – Ph 3 Randomized Study of Dara + Bortezomib + Len + Dex (Dara-VRd) vs VRd Alone in Patients with NDMM Who Are Eligible for Autologous Stem Cell Transplantation (ASCT) - IsKia – Ph 3 Randomized Study of Isatuximab-Carfilzomib-Lenalidomide-Dexamethasone vs Carfilzomib-Lenalidomide-Dexamethasone As Pre-Transplant Induction and Post-Transplant Consolidation in NDMM - Bortezomib Dosing - Retrospective Observational Study on Real-World Bortezomib Prescribing Patterns and Outcomes in NDMM - KarMMA-3 Update - Idecabtagene Vicleucel (ide-cel) vs Standard Regimens in Patients with Triple-Class–Exposed (TCE) RRMM: Updated Analysis

In discussion with Dr. Eleonora Teplinsky, covering the San Antonio Breast Cancer Symposium 2023 Highlights from Community Oncology perspective. We covered 4 important practice informing studies with Dr. Teplinsky: - NSABP B-51 – Loco-regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node Negative After Neoadjuvant Chemotherapy - IDEA Update – Five-year Outcomes of the IDEA trial of Endocrine Therapy Without Radiotherapy After Breast-Conserving Surgery for Postmenopausal Patients Aged 50-69 With Genomically-Selected Favorable Stage I Breast Cancer - ICARO - Nodal Burden and Nodal Recurrence in Patients With Isolated Tumor Cells After Neoadjuvant Chemotherapy Treated with Axillary Dissection or Nodal Radiation - Keynote-522 Update - Event Free Survival with neoadjuvant and adjuvant pembrolizumab in TNBC